<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PERINDOPRIL ERBUMINE</span><br/>(per-in'do-pril)<br/><span class="topboxtradename">Aceon<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">angiotensin-converting enzyme inhibitor</span>; <span class="classification">antihypertensive</span><br/><b>Prototype: </b>Captopril<br/><b>Pregnancy Category: </b>C (first trimester); D (second and third trimesters)<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg, 4 mg, 8 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Angiotensin-converting enzyme (ACE) inhibitor. ACE catalyzes the conversion of angiotensin I to angiotensin II, a vasoconstrictor
         substance. Therefore, angiotensin II levels are decreased by perindopril, thus decreasing vasopressor activity and aldosterone
         secretion.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Lowers BP by inhibition of ACE. Reduced aldosterone is associated with potassium-sparing effect. In addition, decreases systemic
         vascular resistance (afterload) and pulmonary capillary wedge pressure (PCWP), a measure of preload, and improves cardiac
         output as well as activity tolerance.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Hypertension, CHF</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to perindopril or any other ACE inhibitor; history of angioedema induced by an ACE inhibitor, pregnancy [category
         C (first trimester), category D (second and third trimester)]; patients with hypertrophic cardiomyopathy, renal artery stenosis.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Renal insufficiency, volume-depleted patients, severe liver dysfunction; autoimmune diseases, immunosuppressant drug therapy;
         hyperkalemia or potassium-sparing diuretics; older adult; surgery; neutropenia; lactation; febrile illness.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypertension, CHF</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 4 mg once daily, may be increased to 8 mg daily in 1 or 2 divided doses (max:16 mg/d)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> May need to use lower doses in patients with mild to moderate impairment<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Manufacturer recommends an initial dose of 24 mg in 1 or 2 divided doses if concurrently ordered diuretic cannot be
            discontinued 23 d before beginning perinodopril. Consult physician.
         </li>
<li>Give on an empty stomach 1 h before meals.</li>
<li>Dosage adjustments are generally made at intervals of at least 1 wk.</li>
<li>Store at 20°25° C (68°77° F) and protect from moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Dizziness, light-headedness (in the absence of postural hypotension), headache, mood and sleep disorders, fatigue. <span class="typehead">CV:</span> Palpitations. <span class="typehead">Endocrine:</span> Hyperkalemia. <span class="typehead">GI:</span> Nausea, vomiting, epigastric pain, diarrhea, taste disturbances, dyspepsia. <span class="typehead">Urogenital:</span> Proteinuria, impotence, sexual dysfunction. <span class="typehead">Special Senses:</span> Dry eyes, blurred vision. <span class="typehead">Body as a Whole:</span> <span class="speceff-common">Cough,</span> <span class="speceff-life">angioedema</span>, pruritus, muscle cramps, sinusitis, hypertonia, fever. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <span class="classification">potassium-sparing diuretics</span> <b>(amiloride</b>, <b>spironolactone,</b> <b>triamterene)</b> may increase the risk of hyperkalemia. <span class="classification">potassium supplements</span> increase the risk of hyperkalemia. <span class="typehead"> Food:</span> Food can decrease drug absorption 35%. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract, absorption significantly decreased when taken with food. <span class="typehead">Peak:</span> Perindopril: 1 h; perindoprilat: 37 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Metabolism:</span> Hydrolyzed in the liver to its active form, perindoprilat. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> <b>Perindopril:</b> 0.81 h, <b>perindoprilat:</b> 30120 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor BR and HR carefully following initial dose for several hours until stable, especially in patients using concurrent
            diuretics, on salt restriction, or volume depleted.
         </li>
<li>Place patient immediately in a supine position if excess hypotension develops.</li>
<li>Lab tests: Monitor serum potassium, serum sodium, BUN and creatinine, ALT, blood glucose, lipid profile, and WBC with differential
            periodically.
         </li>
<li>Monitor kidney function in patients with CHF closely.</li>
<li>Monitor serum lithium levels and assess for S&amp;S of lithium toxicity frequently when used concurrently; increased caution is
            needed when diuretic therapy is also used.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Discontinue drug and immediately report S&amp;S of angioedema (i.e., swelling) of face or extremities to physician. Seek emergency
            help for swelling of the tongue or any other signs of potential airway obstruction.
         </li>
<li>Be aware that light-headedness can occur, especially during early therapy; excess fluid loss of any kind (e.g., vomiting,
            diarrhea) will increase risk of hypotension and syncope.
         </li>
<li>Avoid using potassium supplements unless specifically directed to do so by physician.</li>
<li>Report S&amp;S of infection (e.g., sore throat, fever) promptly to physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>